Cargando…

Short-term nitisinone discontinuation of hereditary tyrosinemia type 1 mice causes metabolic alterations in glutathione metabolism/biosynthesis and multiple amino acid degradation pathways

Detalles Bibliográficos
Autores principales:	Haaike, Colemonts-Vroninks, Brendan, Norman P., Sven, Van Laere, Andrew, Davison S., Lionel, Marcélis, Georges, Casimir, Philippe, Goyens, Paul, Claes, Dimitri, De Bundel, Geert, Martens, Rao, Ranganath Lakshminarayan, Tamara, Vanhaecke, James A, Gallagher, Joery, De Kock
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chongqing Medical University 2022
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10363636/ https://www.ncbi.nlm.nih.gov/pubmed/37492745 http://dx.doi.org/10.1016/j.gendis.2022.11.013

Ejemplares similares

Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation
por: Colemonts-Vroninks, Haaike, et al.
Publicado: (2020)

Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype
por: Neuckermans, Jessie, et al.
Publicado: (2023)

Neurological Crises after Discontinuation of Nitisinone (NTBC) Treatment in Tyrosinemia
por: HONAR, Naser, et al.
Publicado: (2017)

Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria
por: Hughes, Juliette H., et al.
Publicado: (2020)

Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain
por: Couce, María Luz, et al.
Publicado: (2019)

Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1)
por: Das, Anibh Martin
Publicado: (2017)

Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria
por: Davison, Andrew S., et al.
Publicado: (2022)

Clinical development of nitisinone for alkaptonuria (developakure) - a rare disease clinical trials design
por: Psarelli, Eftychia Eirini, et al.
Publicado: (2013)

Inflammation Alters the Secretome and Immunomodulatory Properties of Human Skin-Derived Precursor Cells
por: De Kock, Joery, et al.
Publicado: (2020)

Long‐term low dose nitisinone therapy in adults with alkaptonuria shows no cognitive decline or increased severity of depression
por: Davison, Andrew S., et al.
Publicado: (2022)

Vitiligo, alkaptonuria, and nitisinone—A report of three families and review of the literature
por: Ranganath, Lakshminarayan, et al.
Publicado: (2021)

Comprehensive Biotransformation Analysis of Phenylalanine-Tyrosine Metabolism Reveals Alternative Routes of Metabolite Clearance in Nitisinone-Treated Alkaptonuria
por: Norman, Brendan P., et al.
Publicado: (2022)

Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet
por: García, María Ignacia, et al.
Publicado: (2017)

Validation of a therapeutic range for nitisinone in patients treated for tyrosinemia type 1 based on reduction of succinylacetone excretion
por: Jack, Rhona M., et al.
Publicado: (2019)

Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review
por: Geppert, Julia, et al.
Publicado: (2017)

Evaluation of the serum metabolome of patients with alkaptonuria before and after two years of treatment with nitisinone using LC‐QTOF‐MS
por: Davison, Andrew S., et al.
Publicado: (2019)

Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients
por: Genovese, Federica, et al.
Publicado: (2023)

Association of alkaptonuria and low dose nitisinone therapy with cataract formation in a large cohort of patients
por: Ahmad, Mohammad S. Z., et al.
Publicado: (2022)

Revisiting Quantification of Phenylalanine/Tyrosine Flux in the Ochronotic Pathway during Long-Term Nitisinone Treatment of Alkaptonuria
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2022)

Reversal of ochronotic pigmentation in alkaptonuria following nitisinone therapy: Analysis of data from the United Kingdom National Alkaptonuria Centre
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2020)

Fatal acute haemolysis and methaemoglobinaemia in a man with renal failure and Alkaptonuria – Is nitisinone the solution?
por: Davison, A.S., et al.
Publicado: (2020)

Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria
por: Ranganath, L. R., et al.
Publicado: (2022)

Radiological evolution of spinal disease in alkaptonuria and the effect of nitisinone
por: Imrich, Richard, et al.
Publicado: (2022)

Metabolic profiles and fingerprints for the investigation of the influence of nitisinone on the metabolism of the yeast Saccharomyces cerevisiae
por: Barchanska, Hanna, et al.
Publicado: (2023)

Comparing the Phenylalanine/Tyrosine Pathway and Related Factors between Keratopathy and No-Keratopathy Groups as Well as between Genders in Alkaptonuria during Nitisinone Treatment
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2022)

Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria
por: Milan, A. M., et al.
Publicado: (2019)

Comparing nitisinone 2 mg and 10 mg in the treatment of alkaptonuria—An approach using statistical modelling
por: Ranganath, Lakshminarayan R., et al.
Publicado: (2021)

Open-Label Single-Sequence Crossover Study Evaluating Pharmacokinetics, Efficacy, and Safety of Once-Daily Dosing of Nitisinone in Patients with Hereditary Tyrosinemia Type 1
por: Guffon, Nathalie, et al.
Publicado: (2017)

Evaluation of Homogentisic Acid, a Prospective Antibacterial Agent Highlighted by the Suitability of Nitisinone in Alkaptonuria 2 (SONIA 2) Clinical Trial
por: Ooi, Nicola, et al.
Publicado: (2023)

Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients
por: van Vliet, Kimber, et al.
Publicado: (2019)

Characterization of changes in the tyrosine pathway by 24-h profiling during nitisinone treatment in alkaptonuria
por: Ranganath, L.R., et al.
Publicado: (2022)

Hepatorenal tyrosinemia
por: KITAGAWA, Teruo
Publicado: (2012)

Preventive use of nitisinone in alkaptonuria
por: Wolffenbuttel, Bruce H. R., et al.
Publicado: (2021)

Adequacy of nitisinone for the management of alkaptonuria
por: Abbas, Khawar, et al.
Publicado: (2022)

The Discovery of the Mode of Action of Nitisinone
por: Lock, Edward A.
Publicado: (2022)

Effects of Nitisinone on Oxidative and Inflammatory Markers in Alkaptonuria: Results from SONIA1 and SONIA2 Studies
por: Braconi, Daniela, et al.
Publicado: (2022)

Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls
por: van Ginkel, Willem G., et al.
Publicado: (2016)

Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery
por: Boeckmans, Joost, et al.
Publicado: (2022)

In Vitro Differentiation of Embryonic and Adult Stem Cells into Hepatocytes: State of the Art
por: Snykers, Sarah, et al.
Publicado: (2009)

Current Status of Human Adipose–Derived Stem Cells: Differentiation into Hepatocyte-Like Cells
por: Al Battah, Feras, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ujgt9ic0j379l2n3indu17iq80